Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Eagle Pharmaceuticals Inc.

$EGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $EGRX alert in real time by email
SC 13G 1 Eagle_Pharmaceuticals.txt 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * Eagle Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 269796108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1 (b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the ACT but shall be subject to all other provisions of the Act (however, see the Notes). SEC 1745 (3-98) CUSIP No.269796108 1. Names of Reporting Persons. Brandes Investment Partners, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0704072 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 299,235 7. Sole Dispositive Power 8. Shared Dispositive Power 745,079 9. Aggregate Amount Beneficially Owned by Each Reporting Person 745,079 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 5.74 % 12. Type of Reporting Person (See Instructions) IA, PN CUSIP No.269796108 1. Names of Reporting Persons. CO-GP, LLC I.R.S. Identification Nos. of above persons (entities only). 73-1677697 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 299,235 7. Sole Dispositive Power 8. Shared Dispositive Power 745,079 9. Aggregate Amount Beneficially Owned by Each Reporting Person 745,079 shares are deemed to be beneficially owned by CO-GP, LLC as a control person of the investment adviser. CO-GP, LLC disclaims any direct ownership of the shares reported in this Schedule 13G, except for an amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 5.74 % 12. Type of Reporting Person (See Instructions) CO, OO (Control Person) CUSIP No.269796108 1. Names of Reporting Persons. Brandes Worldwide Holdings, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0836630 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 299,235 7. Sole Dispositive Power 8. Shared Dispositive Power 745,079 9. Aggregate Amount Beneficially Owned by Each Reporting Person 745,079 shares are deemed to be beneficially owned by Brandes Worldwide Holdings, L.P., as a control person of the investment adviser. Brandes Worldwide Holdings, L.P. disclaims any direct ownership of the shares reported in this Schedule 13G. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 5.74 % 12. Type of Reporting Person (See Instructions) PN, OO (Control Person) CUSIP No.269796108 1. Names of Reporting Persons. Glenn Carlson I.R.S. Identification Nos. of above persons (entities only). 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization USA Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 299,235 7. Sole Dispositive Power 8. Shared Dispositive Power 745,079 9. Aggregate Amount Beneficially Owned by Each Reporting Person 745,079 shares are deemed to be beneficially owned by Glenn Carlson, a control person of the investment adviser. Mr. Carlson disclaims any direct ownership of the shares reported in Schedule 13G, except for the amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 5.74 % 12. Type of Reporting Person (See Instructions) IN, OO (Control Person) Item 1(a) Name of Issuer: Eagle Pharmaceuticals Inc. Item 1(b) Address of Issuers Principal Executive Offices: 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ 07677 Item 2(a) Name of Person Filing: (i) Brandes Investment Partners, L.P. (ii) CO-GP, LLC. (iii) Brandes Worldwide Holdings, L.P. (iv) Glenn Carlson Item 2(b) Address of Principal Business office or, if None, Residence: (i) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (ii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iv) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 Item 2(c) Citizenship (i) Delaware (ii) Delaware (iii) Delaware (iv) USA Item 2(d) Title of Class Securities: Common Shares Item 2(e) CUSIP Number: 269796108 Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(ii)(F). (g) [ ] A parent holding company or control person in accordance with 240.13d- 1(b)(1)(ii)(G). (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). (j) [x] Group, in accordance with 240.13d- 1(b)(1)(ii)(J). This statement is filed by Brandes Investment Partners, L.P., an investment adviser registered under the Investment Advisers Act of 1940, its control persons and its holding company. (See, also, Exhibit A.) Item 4. Ownership: (a) Amount Beneficially Owned: 745,079 (b) Percent of Class: 5.74 % (c) Number of shares as to which the joint filers have: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 299,235 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 745,079 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ?. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. See Exhibit A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification: (a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 8, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner CO-GP, LLC its General Partner CO-GP, LLC By: /s/ Glenn Carlson Glenn Carlson, General Partner BRANDES WORLDWIDE HOLDINGS, L.P. By: /s/ Glenn Carlson Glenn Carlson of CO- GP, LLC its General Partner By: /s/ Glenn Carlson Glenn Carlson, Control Person EXHIBIT A Identification and Classification of Members of the Group Pursuant to Rule 13d-1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, the members of the group making this joint filing are identified and classified as follows: Name: Brandes Investment Partners, L.P. (the Investment Adviser) Classification: Investment adviser registered under Investment Advisers Act of 1940 Co-GP, LLC A control person of the Investment Adviser Brandes Worldwide Holdings, L.P. A control person of the Investment Adviser Glenn Carlson A control person of the Investment Adviser EXHIBIT B Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d- 1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the Act) by and among the parties listed below, each referred to herein as a Joint Filer. The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1. Dated: February 8, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner of Co-GP, LLC. Co-GP, LLC. By: /s/ Glenn Carlson Glenn Carlson, General Partner EXHIBIT C Disclaimer of Beneficial Ownership Co-GP, LLC, Brandes Worldwide Holdings, L.P., Glenn Carlson, and Jeff Busby disclaim beneficial interest as to the shares referenced above, except for an amount equal to substantially less than one percent of the shares reported on this Schedule 13D. None of these entities or individuals holds the above- referenced shares for its/his own account except on a de minimis basis. /s/Glenn Carlson Glenn Carlson /s/Jeff Busby Jeff Busby
Get the next $EGRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EGRX

DatePrice TargetRatingAnalyst
8/10/2023$26.00 → $17.00Neutral → Underweight
Piper Sandler
8/9/2023$26.00 → $17.00Neutral → Underweight
Piper Sandler
More analyst ratings

$EGRX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

    WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. ("Blue Owl") (the "Agreement"), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.   BENDEKA is a ready-to-dilute liquid, low-volume (50 mL) and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphoc

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

    WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that it has notified The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the "SEC") to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC. As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EGRX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EGRX
 SEC Filings

See more

$EGRX
 Leadership Updates

Live Leadership Updates

See more

  • Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

    WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

    WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
 Financials

Live finance-specific insights

See more

  • Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Eagle Delays Third Quarter 2023 Results and Conference Call

    WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more